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T cell activation leads to a dramatic demand for energy and biosynthetic precursors that is met by increased
glucose and glutamine metabolism. In this issue of Immunity, Wang et al. (2011) show that Myc is essential in
T cell metabolic reprogramming.Adaptive immunity requires that lympho-
cytes clonally expand to combat invading
pathogens. Cell division, however, must
be preceded by cell growth. This funda-
mental necessity for growth has propelled
efforts to understand basic mechanisms
to generate essential lipids, nucleic acids,
and proteins. One field that has ap-
proached this challenge head-on is
cancer biology, in which it has been
known for nearly a century that cellular
transformation leads to increased glu-
cose consumption and lactate secretion,
a metabolic program termed aerobic
glycolysis. The key to why cancer would
promote an energy inefficient glycolytic
metabolism has been the realization that
it’s not just the ATP that matters. Rather,
aerobic glycolysis is an ideal metabolic
program to provide biosynthetic sub-
strates. In this issue of Immunity, Wang
et al. (2011) address the role of the onco-
genic transcription factor Myc in T cell
activation to show it plays an essential
role in the metabolic switch that supports
T cell growth.
If proliferation leads to a sharp increase
in metabolic demands, stimulated T cells
are as demanding as any mammalian
cell. After an initial lag, activated T cells
can cycle extremely quickly, with a
doubling of mass and cell division as
rapidly as every 4 to 6 hr. To support this
robust growth, activated T cells quickly
increase glucose uptake and glycolysis
as well as glutamine metabolism and
become, in metabolic respects, very
similar to cancer cells. This metabolic
switch is essential for T cell proliferation
and function, given that inhibition of
glucose or glutamine metabolism can
prevent growth and division as well as
selectively impair some cytokine produc-
tion of activated T cells (Jacobs et al.,
2008; Wang et al., 2011). Conversely,increased glucose uptake by transgenic
expression of the glucose transporter
Glut1 can strengthen T cell responses
(Jacobs et al., 2008). These findings
suggest that targeting metabolism may
be a new strategy to modulate immunity.
A key question that remains is how are
these metabolic programs regulated?
Evidence is now emerging that the very
same mechanisms that drive aerobic
glycolysis in cancer are responsible for
themetabolic reprogramming of activated
T cells. This is perhaps not surprising
because many of the same signaling
pathways that drive oncogenesis and the
metabolic phenotype of tumors are acti-
vated and essential upon lymphocyte
stimulation. The best example is the post-
translational regulation of aerobic glycol-
ysis by the Akt and mTOR pathway. This
pathway is a promising target to suppress
cancer cell growth and is also critical for
T cell activation and effector function.
The transcriptional regulation of T cell
metabolism, however, has been largely
unclear. Many proteins could fill this role,
but Myc has been a prime candidate to
transcriptionally promote T cell glycolysis
given its clear role in the metabolic
program of cancer cells (Dang et al.,
2009) as well as T cell development and
function (Douglas et al., 2001).
Starting with the expression of a variety
of genes involved in glucose and gluta-
mine metabolism, Wang et al. undertook
a computational approach to identify tran-
scription factors that are likely to drive
metabolic reprogramming in T cell activa-
tion. Although a number of interesting
transcription factors were suggested,
two of the top candidates were Myc and
hypoxia inducible factor-1a (HIF-1a).
Using Myc- and HIF-1a-deficient T cells,
the authors then showed by measure-
ment of gene expression, metaboliteImmunity 35, Dlevels, and flux through metabolic path-
ways that acute loss of Myc, but surpris-
ingly not HIF-1a, dramatically suppressed
metabolic reprogramming in the initial day
after T cell activation that leads to the
onset of rapid cell divisions.
Myc has a large number of potential
gene targets and it could be argued that
failure to upregulate expression of meta-
bolic genes may not be entirely due to
failure of specific Myc association and
regulation of these genes. Rather, the crit-
ical role for Myc in another process, such
as cell cycle regulation or ribosome
biogenesis, may lead to a feedback to
control the expression of metabolic
genes. Although direct binding of Myc to
metabolic targets in T cells remains to be
formally established, Myc is well known
to directly bind and regulatemany of these
samemetabolic genes in other settings. A
further consideration is that T cells do not
enter the cell cycle until long after initial
stimulation. Changes in T cell metabolism
were observed, however, within 3 to 10 hr
of stimulation. Thus, the metabolic effects
ofMyc, direct or otherwise,were rapidand
appear to be cell cycle independent.
The metabolic pathways in particular
that stood out as Myc dependent were
glycolysis, glutamine oxidation, and poly-
amine synthesis (Figure 1). Glucose and
glutamine metabolism would be antici-
pated on the basis of the role of Myc in
these pathways in cancer cells (Dang
et al., 2009). The Myc-dependent regula-
tion of polyamine synthesis, however,
was more unexpected and may indicate
a previously unappreciated regulation of
these important metabolites in T cells.
Indeed, ornithine decarboxylase, which
can promote polyamine synthesis, has
been shown to be a Myc target and is
essential for lymphomagenesis (Nilsson
et al., 2005). Polyamine metabolism andecember 23, 2011 ª2011 Elsevier Inc. 845
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Figure 1. Regulatory Mechanisms that Control T Cell Metabolic
Reprogramming in Activation
T cell activation leads to increased glucose, glutamine, and mitochondrial
oxidative metabolism that are essential for cell growth and proliferation.
Data presented by Wang et al. (2011) shows Myc plays a key role in upregula-
tion of glucose, glutamine, and polyamine metabolism. In addition, the
Akt-mTOR pathway promotes posttranslational events in aerobic glycolysis,
and ERRa may play a role in regulating mitochondrial metabolism in T cell
activation.
Immunity
Previewsmolecular functionarenotwell
understood, and this may be
a case inwhich T cell metabo-
lism research may inform the
cancer cell metabolism field.
Equally intriguing as the
pathways that were Myc
dependent were the path-
ways that were neither Myc
norHIF-1adependent. In par-
ticular, mitochondrial path-
ways were not strongly
affected by Myc deficiency,
given that lipid oxidation de-
creased and oxygen con-
sumption increased in T cell
activation regardless of Myc
or HIF-1a status. Clearly,
T cell metabolism is regulated
in a somewhat piecemeal
fashion and additional factors
also contribute to regulate
specific arms of the meta-bolic program. For example, the nuclear
hormone receptor estrogen-related re-
ceptor-a (ERRa) can also play a role in
T cell metabolism and may mediate the
mitochondrial arm of T cell metabolic re-
programming (Michalek et al., 2011b).
HIF-1amay also be involved, albeit at later
times and in specific T cell subsets, such
as Th17 cells (Shi et al., 2011). The cumu-
lative action of thesemultiple transcription
factors, together with posttranslational
regulation, provides flexibility to coordi-
nate T cell metabolic reprogramming in
distinct settings (Figure 1).
Observations that T cell metabolic
programming occurs through a set of
regulatory events open important new
doors to understand fundamental T cell
biology. A challenge, however, is to
extend beyond correlation of cellular
metabolic phenotype and functional
outcome. As this field grows, therefore,
it is important to directly manipulate the
specific metabolic pathways in question
to determine their role and sufficiency to
impact T cell activity. This is a daunting
prospect, however, because a coordi-
nated action of multiple metabolic path-
ways is likely to be essential and replace-
ment of a single metabolite or metabolic
gene may simply be insufficient. Never-
theless, Wang et al. do address this
challenge and show that addition of
polyamines can partially rescue the
limited cell division of T cells upon gluta-
mine deficiency. Specific metabolic path-846 Immunity 35, December 23, 2011 ª2011ways that are Myc dependent, therefore,
are key components of T cell growth and
proliferation.
One additional unresolved issue in this
study and in the field of T cell metabolism
ingeneral is howmetabolic changesoccur
and regulate T cell function in vivo. Wang
et al. (2011) show that the inhibition of
Myc clearly prevented T cell proliferation
in vivo. Likewise, inhibition of glucose or
glutamine metabolism by whole-animal
treatmentwithglycolysis or glutaminolysis
inhibitors also prevented T cell prolifera-
tion in vivo. Given that antigen-presenting
andother cells alsoutilize thesepathways,
however, it is unclear to what extent T cell
metabolism itself is limiting andwhat path-
ways may be most important in vivo.
T cells isolated during an acute graft-
versus-host reaction, for example, appear
to be highly sensitive to inhibition of mito-
chondrial rather than glucose metabolism
(Gatza et al., 2011). The in vitro environ-
ment has been highly optimized for
maximal cell growth and thedifferent array
of nutrients and stimuli in vivo may have
a critical effect on T cell metabolism and,
therefore, howTcells respond to inhibition
of metabolic pathways.
In the end, much as the field of cancer
metabolism has a goal of targeting
aerobic glycolysis to control or eliminate
cancer, targeting the metabolic pheno-
type of activated T cells may provide
a new approach to immunosuppression.
A key consideration in these efforts thatElsevier Inc.goes beyond investigation of
the initial steps of T cell activa-
tion described by Wang et al.
is the differentiation of T cells
into specific effector, regula-
tory, or memory cell subsets.
Importantly, each CD4 T cell
effector subset appears to
have a distinct metabolic
character from regulatory
T cells (Michalek et al.,
2011a; Shi et al., 2011) and
memory CD8 T cells (Pearce
et al., 2009), given that the
latter primarily utilize lipids
rather than glucose as ameta-
bolic fuel. Thus, targeting the
aerobic glycolysis of T cells
has the potential to selectively
impede effector, but not regu-
latory or memory T cells.
Understanding the regulation
of metabolism in T cell activa-tion has great potential to modulate
immunity and the clear identification of
Myc in this process is a strong step
forward.
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